Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 32.60M
March 31, 2026 38.78M
December 31, 2025 -93.56M
September 30, 2025 21.47M
June 30, 2025 24.33M
March 31, 2025 29.33M
December 31, 2024 17.90M
September 30, 2024 -98.17M
June 30, 2024 29.54M
March 31, 2024 10.79M
December 31, 2023 6.571M
September 30, 2023 -56.59M
June 30, 2023 -1.006M
March 31, 2023 -6.095M
December 31, 2022 -59.21M
September 30, 2022 33.00M
June 30, 2022 25.20M
March 31, 2022 53.66M
December 31, 2021 -1.268M
September 30, 2021 12.98M
June 30, 2021 -3.432M
March 31, 2021 -77.74M
December 31, 2020 -0.381M
September 30, 2020 -6.861M
June 30, 2020 18.08M
Date Value
March 31, 2020 -1.785M
December 31, 2019 16.75M
September 30, 2019 6.59M
June 30, 2019 -14.92M
March 31, 2019 7.32M
December 31, 2018 0.869M
September 30, 2018 -35.71M
June 30, 2018 11.83M
March 31, 2018 9.39M
December 31, 2017 -39.05M
September 30, 2017 -33.44M
June 30, 2017 3.441M
March 31, 2017 -0.059M
December 31, 2016 0.00
September 30, 2016 -0.003M
June 30, 2016 -4.383M
March 31, 2016 4.378M
December 31, 2015 -0.296M
September 30, 2015 4.431M
June 30, 2015 -0.221M
March 31, 2015 -0.519M
December 31, 2014 -4.401M
September 30, 2014 2.812M
June 30, 2014 -0.3919M
March 31, 2014 2.462M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. -10.35B
Insmed, Inc. 24.51M
United Therapeutics Corp. 87.50M
Vertex Pharmaceuticals, Inc. -45.80M
SELLAS Life Sciences Group, Inc. 0.00